Dexcom G8 News
Dexcom just announced a lot. Here's what actually matters.
A new sensor called G8. A glucose-plus-potassium sensor for kidney and heart disease. Smart Bolus. Smart Basal. A hospital product. A new T2 sensor called Flex. Stelo going international. I read the deck so you don't have to.
Dexcom held their Investor Day earlier today. Usually these events are for Wall Street and they're mostly about gross margins and cash flow conversion. But this one had real product news in it — more than I expected, honestly — so I wanted to walk through it for you.
I'm going to skip the financial chart talk and focus on the things that actually affect the person wearing the sensor: what's shipping now, what's coming, and what to make of it.
G7 15 Day: the rollout, by the numbers
Dexcom shared four concrete updates on the G7 15 Day:
~50% by year-end
Dexcom expects about half of their US customer base to be on the 15 Day platform by the end of 2026. If you haven't switched yet, that's the wave you'd be joining.
All US partners now live
15 Day is now available with all US pump partners. If you've been waiting on Tandem or another integration, that's done.
Launching 2H 2026
International rollout of the 15 Day begins in the second half of this year. Specific country sequencing wasn't broken out.
15 Day is now baseline
Dexcom called it directly: 15 day wear is the new baseline for their product portfolio. Everything they build going forward assumes that as the floor.
Smart Basal and Smart Bolus
Dexcom highlighted software features that use CGM data to do something, not just show you the number. Two named products:
Smart Basal
For people starting or optimizing basal insulin — primarily a Type 2 use case. Today, when a doctor starts someone on basal insulin, getting the dose right typically takes about 12 weeks of back-and-forth: log review, dose adjustments, follow-up visits. Dexcom is saying Smart Basal can shrink that to fewer than 30 days with personalized dosing recommendations driven by the CGM data.
That's the kind of thing that sounds incremental until you imagine it happening millions of times a year. Faster time to a working dose means less hyperglycemia exposure during the titration period, which is a real health outcome.
Smart Bolus
This one is more relevant to the T1D community. Smart Bolus uses CGM trend data to inform bolus calculations — the goal being to reduce hypoglycemia risk, reduce missed doses, and avoid insulin stacking. The feature is described as under review and not currently available, but it's on the roadmap and Dexcom is being public about it.
The framing here matters. Adding the trend — is your glucose rising fast, falling, flat? — is what humans already do mentally if they're paying attention. Building it into the device is a meaningful step.
If Smart Bolus ends up working the way it's described, it's the kind of feature that helps the person who isn't already a power user. That's a lot of people.
— My takeMeet G8
A sensor that adapts during wear
This is the headline product news from the day. G8 is the next-generation Dexcom sensor, and it's expected to launch in late 2027 or early 2028. The big idea: existing CGMs are optimized in the factory through calibration and process control. Once it's on you, the sensor is doing its best with what it knew at the moment it was made. G8 changes that.
Dexcom is describing G8 as self-adapting — updated sensor electronics and algorithm innovation that lets it adjust in real time during wear. The company says G8 represents technology in development for nearly two decades. They're claiming significant accuracy improvements over G7 and a reduction in outlier readings. They also say G8 is 50% smaller than G7.
Why this matters for you
Two things. First, accuracy and reliability are the things CGM customers consistently ask for above everything else. In Dexcom's own research, those two attributes top the list of what customers expect — above ease of use, support, brand, anything. The top two reasons people stop using a CGM are both about reliability. If G8 delivers what Dexcom is claiming, it directly addresses the thing the community has been asking for.
Second, smaller hardware matters more than people give it credit for. Pediatric use, lean people, athletes, anyone wearing the sensor on the arm — a smaller sensor is a more wearable sensor, full stop.
This won't ship for roughly two years. But it's the thing to keep an eye on.
Two more G8 notes from the Q&A
Two items from the Q&A session that didn't make the slides: Dexcom expects to submit G8 to the FDA in 2027, on the way to that late 2027 / early 2028 consumer launch. And ketone monitoring is planned to be part of the G8 platform — not at launch, but on the roadmap.
The glucose + potassium sensor (CGPM)
Continuous glucose and continuous potassium, in one sensor
This is the one I want you to pay attention to even if it doesn't apply to you today. Dexcom announced they're working on a multi-analyte sensor — one that measures glucose and potassium continuously. They're calling it CGPM.
Why potassium? Because for people with Type 2 diabetes, chronic kidney disease (CKD) and cardiovascular disease (CVD) are massive comorbidities. About a third of people with Type 2 have CKD; about a third have CVD. In those populations, potassium imbalances are associated with higher rates of ICU admission, longer hospital stays, and higher mortality. Dexcom's data says roughly 20% of annual costs for people with T2D plus CKD are tied to potassium problems.
A sensor that watches both glucose and potassium in real time could change how those patients are managed.
What this means for the T1D community
If you have Type 1 and no kidney or heart involvement, CGPM is interesting but not immediately for you. But — and this is worth saying out loud — kidney disease is a long-tail risk that anyone with diabetes can develop. A sensor that watches potassium continuously could matter to a lot more people than you might think today.
Dexcom didn't give a CGPM timeline. They positioned it under "what's next" and "we can do more."
Other things on the way
A few more product announcements that didn't get headline space but are worth knowing about:
- Dexcom Flex A new sensor designed for people with Type 2 diabetes — both basal-insulin and non-insulin users. Launching soon in Germany. International only for now. This is part of Dexcom's effort to tier the portfolio so different products fit different reimbursement environments.
- Stelo going international The over-the-counter biosensor (no prescription needed, aimed at the wellness market and people with T2 not on insulin) is launching in Australia, the UK, South Korea, and New Zealand in late 2026 / early 2027.
- A Dexcom hospital CGM system Dexcom plans to launch an inpatient hospital product by the end of 2027. If you've ever had a kid or family member admitted with a DKA and had to advocate for keeping the CGM on, this is relevant. There are roughly 14 million annual dysglycemic events in hospitals.
- Direct EHR integration More than 320 health systems are now live or onboarding with Dexcom's direct EHR integration (which works across multiple platforms, including Epic / MyChart). Translation: your CGM data shows up in your endo's chart alongside your labs, without your endo needing to log into a separate platform. This is a slow-burn quality-of-life improvement that pays off over years.
Why coverage expansion changes everything
One last thing worth understanding, because it's the engine behind everything else: Dexcom is expecting CMS (Medicare) to expand coverage to all people with Type 2 diabetes — including those not on insulin — by mid-2027. They expect a CMS proposal at the end of 2026 and final coverage by mid-2027.
That single change is expected to roughly double Dexcom's covered lives in the US, from about 15 million today to about 30 million by 2027. In plain terms: a lot more people will have a CGM paid for by insurance.
Why that matters to you, even if you're already covered: when a sensor company has 30 million covered lives instead of 15 million, the math on every R&D dollar, every algorithm improvement, every manufacturing optimization changes. The same Dexcom that's developing G8 and CGPM is going to be a meaningfully larger company a year from now, with more resources to invest in the things you actually use.
So what do I think?
I think this was a real Investor Day. It had actual products on it, with names and dates, and the dates aren't ten years out. G8 is roughly two years away. Smart Basal already has data behind it. CGPM is further out but it's the most interesting bet in the deck.
The thing I keep coming back to is the slide where the company says "we want to be the premier glucose sensing solution for all" — and this deck pairs it with a roadmap of specific products. For a community that has spent a decade waiting for things, that's worth noticing.
If you have questions about any specific product, send them my way through the private Facebook group or the contact form. I read everything.
Read the full disclaimer
